TY - JOUR
T1 - The repeatability of tests for dry eye signs and symptoms in the dry eye assessment and management (DREAM) study
AU - the DREAM Research Group
AU - Chen, Anna
AU - Augello, Patrick
AU - Asbell, Penny
AU - Ying, Gui Shuang
N1 - Publisher Copyright:
© 2024 British Contact Lens Association
PY - 2024
Y1 - 2024
N2 - Purpose: To assess the repeatability of measures for dry eye disease (DED) symptoms and signs in the DREAM study. Methods: At screening and baseline visits approximately 2 weeks apart, participants were assessed for symptoms by Ocular Surface Disease Index (OSDI) and Brief Ocular Discomfort Index (BODI), and signs by the same physician in the same order: tear break-up time (TBUT), corneal staining, conjunctival staining, Meibomian gland evaluation, and the Schirmer test. The repeatability of DED symptoms and signs was assessed by interclass correlation coefficient (ICC), 95 % limits of agreement, and the percent of eyes with inter-visit difference above the clinically significant threshold. Results: Among 1046 eyes (523 participants), ICC for signs ranged from 0.53 (TBUT) to 0.73 (corneal staining). A substantial percentage of eyes showed clinically significant inter-visit differences: ≥2 points in 17.8 % of eyes for conjunctival staining; ≥3 points in 18.8 % for corneal staining; >2 s in 14.1 % for TBUT; ≥5 mm/5 min in 29.9 % for the Schirmer test, and ≥ 2 points in 27.5 % for Meibomian gland plugging and lid secretion. The OSDI and BODI had ICC of 0.64 and 0.63 respectively, and nearly 40 % of participants had inter-visit score differences ≥ 10 points. Conclusion: In DREAM participants with moderate-to-severe DED, DED signs and symptoms had moderate repeatability, with ocular surface staining scores being the most repeatable and TBUT the least repeatable. A notable percentage of participants had inter-visit differences above the clinically meaningful threshold. These test–retest variabilities in DED signs and symptoms should be considered for designing clinical trials and monitoring disease progression.
AB - Purpose: To assess the repeatability of measures for dry eye disease (DED) symptoms and signs in the DREAM study. Methods: At screening and baseline visits approximately 2 weeks apart, participants were assessed for symptoms by Ocular Surface Disease Index (OSDI) and Brief Ocular Discomfort Index (BODI), and signs by the same physician in the same order: tear break-up time (TBUT), corneal staining, conjunctival staining, Meibomian gland evaluation, and the Schirmer test. The repeatability of DED symptoms and signs was assessed by interclass correlation coefficient (ICC), 95 % limits of agreement, and the percent of eyes with inter-visit difference above the clinically significant threshold. Results: Among 1046 eyes (523 participants), ICC for signs ranged from 0.53 (TBUT) to 0.73 (corneal staining). A substantial percentage of eyes showed clinically significant inter-visit differences: ≥2 points in 17.8 % of eyes for conjunctival staining; ≥3 points in 18.8 % for corneal staining; >2 s in 14.1 % for TBUT; ≥5 mm/5 min in 29.9 % for the Schirmer test, and ≥ 2 points in 27.5 % for Meibomian gland plugging and lid secretion. The OSDI and BODI had ICC of 0.64 and 0.63 respectively, and nearly 40 % of participants had inter-visit score differences ≥ 10 points. Conclusion: In DREAM participants with moderate-to-severe DED, DED signs and symptoms had moderate repeatability, with ocular surface staining scores being the most repeatable and TBUT the least repeatable. A notable percentage of participants had inter-visit differences above the clinically meaningful threshold. These test–retest variabilities in DED signs and symptoms should be considered for designing clinical trials and monitoring disease progression.
KW - Clinical trials
KW - Dry eye disease
KW - Repeatability
KW - Signs
KW - Symptoms
UR - http://www.scopus.com/inward/record.url?scp=85208018810&partnerID=8YFLogxK
U2 - 10.1016/j.clae.2024.102322
DO - 10.1016/j.clae.2024.102322
M3 - Article
AN - SCOPUS:85208018810
SN - 1367-0484
JO - Contact Lens and Anterior Eye
JF - Contact Lens and Anterior Eye
M1 - 102322
ER -